Immunodominance and tumor escape.

Cancers in mouse and man express multiple tumor-specific as well as tumor-associated antigens. Immunodominance in the host response to these antigens can result in successive selection of heritable antigen loss variants. Immunodominance may also prevent the development of responses to new tumor-specific antigens that may arise during tumor progression. Some tumor-specific antigens are retained during tumor progression possibly because they are essential for survival of the malignant phenotype. Immunodominance may allow cancer cells to escape even after loss of a single MHC Class I allele because cross-presentation of the retained antigen by this allele that must be expressed on the surrounding antigen presenting cells sustains the immunodominant response. This prevents effective responses to secondary antigens that may remain as potential targets. Immunization with in vitro selected cancer cell variants that lack the immunodominant antigen can break the immunodominance and prevent escape of cancers from host immunity.

[1]  J. Klein,et al.  Ir-genes in H-2 regulate generation of anti-viral cytotoxic T cells. Mapping to K or D and dominance of unresponsiveness , 1978, The Journal of experimental medicine.

[2]  D. Rowley,et al.  A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens , 1993, The Journal of experimental medicine.

[3]  H. Schreiber,et al.  A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target , 1993, The Journal of experimental medicine.

[4]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[5]  H. Köhler,et al.  Clonal Restriction of the Immune Response to Phosphorylcholine , 1974, Nature.

[6]  P. Monach,et al.  A unique tumor antigen produced by a single amino acid substitution. , 1995, Immunity.

[7]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[8]  J. Shabanowitz,et al.  The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68 , 1997, The Journal of experimental medicine.

[9]  P. Wettstein,et al.  Immunodominance in the immune response to “multiple” histocompatibility antigens , 2004, Immunogenetics.

[10]  F. Brasseur,et al.  A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.

[11]  J. Kirkwood,et al.  Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading , 2000, Immunological investigations.

[12]  C. Waes,et al.  Immunodominant deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro , 1996 .

[13]  F. Garrido,et al.  HLA and cancer: from research to clinical impact. , 1998, Immunology today.

[14]  H. Schreiber,et al.  Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Mulé,et al.  Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[17]  H. Schreiber,et al.  Multiple tumour-specific antigens expressed on a single tumour cell , 1983, Nature.

[18]  P. Grufman,et al.  Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery. , 1998, Journal of immunology.

[19]  G. Klein,et al.  Evolution of tumours and the impact of molecular oncology , 1985, Nature.

[20]  C. Van Waes,et al.  Pecking order among tumor‐specific antigens , 1984, European journal of immunology.

[21]  S. H. van der Burg,et al.  Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.

[22]  J. Bennink,et al.  Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype , 1978, The Journal of experimental medicine.

[23]  H. Schreiber,et al.  Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones. , 1983, Journal of immunology.

[24]  J. Davie,et al.  CLONAL NATURE OF THE IMMUNE RESPONSE TO PHOSPHORYLCHOLINE , 1974, The Journal of experimental medicine.

[25]  H. Schreiber,et al.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells , 1992, The Journal of experimental medicine.

[26]  E. Appella,et al.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.

[27]  W. Storkus,et al.  B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .

[28]  J. Bluestone,et al.  Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.

[29]  P. Coulie,et al.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Melief Cj,et al.  Prospects for T Cell Immunotherapy of Tumours by Vaccination with Immunodominant and Subdominant Peptides , 1994 .

[31]  M. Kripke,et al.  Stepwise immunologic selection of antigenic variants during tumor growth. , 1986, Journal of immunology.

[32]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[33]  C. Van Waes,et al.  Multiple cancers. Tumor burden permits the outgrowth of other cancers , 1985, The Journal of experimental medicine.